Novacyt

ALNOV

FR0010397232

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 10:41:21 2024-04-25 am EDT			5-day change	1st Jan Change
0.8 ^EUR	-4.76%		+6.67%	+12.20%

Apr. 19	Novacyt: confident ahead of DHSC trial	CF
Apr. 19	Novacyt expects court to dismiss application by UK DHSC	AN

Novacyt S.A. Announces Unaudited Revenue Results for the First Quarter Ended March 31, 2021

April 09, 2021 at 07:30 am EDT

Novacyt S.A. announced unaudited revenue results for the first quarter ended March 31, 2021. For the quarter, the company delivered revenue of €83.0 million.

Latest news about Novacyt

Novacyt: confident ahead of DHSC trial	Apr. 19	CF
Novacyt expects court to dismiss application by UK DHSC	Apr. 19	AN
Novacyt expects court to dismiss application by UK DHSC	Apr. 19	AN
AIM WINNERS & LOSERS: Ethernity loss narrows; Fonix staff sell shares	Apr. 19	AN
Yourgene CEO to become head of Novacyt after acquisition	Apr. 11	AN
Novacyt: changes to the Board of Directors	Apr. 11	CF
Novacyt's New CEO to Start May	Apr. 11	MT
Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024	Apr. 11	CI
Novacyt S.A. Announces CEO Changes, Effective on May 1, 2024	Apr. 11	CI
FTSE 100 Closes Up 0.9%, Lifted by BP	Feb. 06	DJ
Novacyt says talks to sell Taiwan laboratory are terminated	Feb. 06	AN
Novacyt: Taiwanese laboratory retained	Feb. 06	CF
Novacyt's Discussions for Taiwanese Unit Sale Fall Through	Feb. 06	MT
Treatt revenue falls; Secure Trust profit picks up	Jan. 25	AN
Novacyt appoints new CFO	Jan. 02	CF
Novacyt promotes Finance Director Steve Gibson to CFO	Jan. 02	AN
Novacyt Names Finance Director as New CFO	Jan. 02	MT
Novacyt notes delay of divestment as awaits approvals	Dec. 21	AN
FTSE 100 Closes Down 0.3% Dragged by Oil Stocks	Dec. 21	DJ
Novacyt: sale to Taiwan not finalized before 2024	Dec. 21	CF
Novacyt Delays Closure of Yourgene Health Taiwan's Sale	Dec. 21	MT
Actual Experience appoints administrators	Nov. 07	AN
Novacyt: IVDR accreditation for Yourgene DPYD test	Nov. 07	CF
Novacyt Receives EU Certification for Cancer Enzyme Deficiency Diagnosis; Shares Soar	Nov. 07	MT
Novacyt S.A. Announces IVDR Certification for DPYD Genotyping Assay	Nov. 07	CI

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
NOVACYT	+12.20%	63.32M
MIMEDX GROUP, INC.	-33.01%	949M
NIBEC CO., LTD.	-18.52%	131M
KIM FOREST ENTERPRISE CO., LTD.	+7.05%	60.9M
COLLPLANT BIOTECHNOLOGIES LTD.	-16.28%	61.96M
BONUS BIOGROUP LTD.	+0.60%	52.2M

Bio Medical Devices

Novacyt

Equities

ALNOV

FR0010397232

Biotechnology & Medical Research

Novacyt S.A. Announces Unaudited Revenue Results for the First Quarter Ended March 31, 2021

Latest news about Novacyt

Chart Novacyt

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Medical Devices